Companies: 10,795·Total market cap: $144.5T
Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc.

GRCLNASDAQHealthcare
$10.25
+$0.01(+0.05%)
Market Cap$197973420
P/E Ratio—
52W High$10.435
52W Low$1.4
Overview
Foreign Private Issuer · Files 20-F / 6-K

Gracell Biotechnologies Inc. (GRCL) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001826492 · GRCL · NASDAQ · as of Jun 9, 2026

Filing snapshot

148
Total Filings
15-12G
Latest Form
2024-03-04
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001826492 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2023-04-25
Fiscal Year End
Apr 25, 2023
Accession No.
0001104659-23-049599
Primary Document
grcl-20221231x20f.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001826492 · Accession 0001104659-23-049599

Latest Key Filings

6-KQuarterly Report
FORM 6-K
2024-02-22
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
15-12G15-12G
15-12G
2024-03-04
View
EFFECTEFFECT
EFFECT
2024-02-27
View
EFFECTEFFECT
EFFECT
2024-02-27
View
S-8 POSS-8 POS
S-8 POS
2024-02-26
View
POS AMPOS AM
POS AM
2024-02-26
View
POS AMPOS AM
POS AM
2024-02-26
View
S-8 POSS-8 POS
S-8 POS
2024-02-26
View
25-NSE25-NSE
25-NSE
2024-02-22
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2024-02-22
View
6-KCurrent Report (Foreign Issuer)
FORM 6-K
2024-02-20
View
SC 13G/ABeneficial Ownership Report (Amended)
SC 13G/A
2024-02-14
View
SC 13G/ABeneficial Ownership Report (Amended)
SC 13G/A
2024-02-14
View
SC 13GBeneficial Ownership Report
Beneficial Ownership Report
2024-02-14
View
SC 13G/ABeneficial Ownership Report (Amended)
AMENDMENT NO. 1 TO SCHEDULE 13G
2024-02-13
View
SC 13G/ABeneficial Ownership Report (Amended)
AMENDMENT NO. 1 TO SCHEDULE 13G
2024-02-13
View
Showing 1–15 of 139 filingsForm 4 / 144 hidden· 148 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001826492  |  Exchange: NASDAQ · Healthcare

Gracell Biotechnologies Inc. (NASDAQ: GRCL) has submitted 148 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001826492, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Gracell Biotechnologies Inc.'s most comprehensive regulatory disclosure. The most recent Gracell Biotechnologies Inc. 10-K was filed on 2023-04-25 for fiscal year ending 2023. Historical GRCL 10-K annual reports are available from 2020 through 2023.

Investors researching Gracell Biotechnologies Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
EQRX SEC Filings →VECT SEC Filings →VERV SEC Filings →PSTX SEC Filings →ALBO SEC Filings →HARP SEC Filings →CMRX SEC Filings →CBIO SEC Filings →
→ GRCL Financials→ GRCL Earnings→ GRCL Insider Trades

Frequently Asked Questions

GRCL SEC Filings · 8 questions

Gracell Biotechnologies Inc. (GRCL) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 148 filings and access original documents at no cost. Gracell Biotechnologies Inc.'s CIK is 0001826492.

GRCL SEC filingsGracell Biotechnologies Inc. SEC documentsfind GRCL 10-K